At a glance
ClinicalIndex Comparison RecordN/ACompleted· 68,563 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characterization of Patients With Geographic Atrophy (GA) in the US
In Brief
An observational study for Geographic Atrophy. Completed, enrolled 68,563 participants across 1 site.
Detailed Summary
To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartMay 2023
First PostedJun 2023
Primary CompletionDec 2023
TodayJul 2026
First PostedJun 6, 2023
Enrollment StartMay 31, 2023
Primary CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.1 years ago